Skip to main content
StemCell Longevita

Neurology

What can MSC therapy realistically offer in Parkinson's disease?

Written by
StemCell Longevita Editorial Team
Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

Parkinson's attracts more overclaiming than almost any other indication. This page separates what is under study from what is being sold.

Medically reviewed by:
Prof. Dr. Erdal Karaöz, PhD
Last reviewed:
Next review:

The short answer

MSC therapy in Parkinson's is early-stage research, not established treatment. Small human studies report acceptable safety and some symptom-scale changes, but there is no robust randomised evidence that it restores dopaminergic neurons or alters disease course. We treat it as an adjunct discussed alongside optimised neurology care, never as a replacement for it.

Who this decision applies to

Usually appropriate to discuss

  • Confirmed diagnosis by a movement-disorder neurologist
  • Medication already optimised, with a current UPDRS assessment on file
  • Patient and family who understand this is supportive and exploratory
  • Ability to attend structured follow-up at three, six and twelve months

Not appropriate right now

  • Patients told to stop or reduce levodopa in order to receive cell therapy
  • Advanced disease with severe cognitive impairment where burden outweighs any plausible benefit
  • Undiagnosed parkinsonism that has not been distinguished from atypical syndromes
  • Families seeking a cure or the discontinuation of neurology follow-up

Evidence at a glance

The same five questions we ask of every indication, answered for this one.

Evidence maturity for Parkinson's: what MSC therapy can and cannot do
QuestionAnswerWhat that means here
Human studies published?YesPhase 1 and small phase 2 human studies of MSCs in Parkinson's are published.
Randomised controlled trials?LimitedFew randomised, controlled and blinded trials; most published work is uncontrolled.
Objective outcome measures?YesUPDRS and quality-of-life scales are the usual measures reported.
Long-term follow-up (≥12 months)?LimitedFollow-up beyond twelve months is rarely reported.
Approved as a routine therapy?NoNo regulatory approval anywhere for MSC therapy as a Parkinson's treatment.

How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.

Options compared, including doing nothing

Realistic options for Parkinson's: what MSC therapy can and cannot do
OptionWhat it can realistically doMain trade-off
Optimised medical therapyThe best-evidenced symptom control availableEffect wanes over years; side effects accumulate
Deep brain stimulationStrong evidence in selected patients with motor fluctuationsNeurosurgical risk and strict selection criteria
MSC therapy as an adjunctUnder study; safety acceptable in published seriesNo proof of disease modification; must not replace medication
Enrol in a registered trialContributes to the evidence and includes structured monitoringEligibility is narrow and placebo allocation is possible
Do nothing beyond current careEntirely reasonable; avoids cost and travelLeaves symptom burden unchanged

How the decision is made in practice

  1. We require the neurologist's letter, current medication list and a recent UPDRS score.
  2. We confirm the diagnosis is idiopathic Parkinson's and not an atypical syndrome, because prognosis and expectations differ sharply.
  3. We state, in writing, that cell therapy is adjunctive and that neurology care continues unchanged.
  4. We agree outcome measures and review dates before any treatment is scheduled.
  5. If the family's expectation is cure or medication withdrawal, we stop the process at this point.

When we decline, and why

  • Any request to reduce or stop dopaminergic medication
  • Severe dementia or care needs that make travel and follow-up unrealistic
  • Atypical parkinsonism where published evidence is absent
  • Expectations that cannot be corrected during consultation

Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.

Questions worth asking any clinic

  • What exactly is being measured, and by whom, at each follow-up point?
  • Is my neurologist being copied into the treatment record?
  • What published human evidence exists for this protocol in Parkinson's specifically?
  • What is the plan if there is no measurable change at six months?

Frequently asked questions

There is no human evidence that it does. Proposed mechanisms are immunomodulatory and paracrine — reducing inflammatory signalling and supporting surviving cells — not cell replacement. Cell-replacement work in Parkinson's is a separate research field using dopaminergic progenitors, still in trials.

No. Stopping dopaminergic medication can be dangerous, and no clinic should ask you to. We will not treat a patient who has been advised to withdraw medication in order to qualify.

Uncontrolled series without blinding, in a condition with a strong placebo response and day-to-day symptom variability, will produce impressive-looking numbers. That is why we weight randomised and blinded data far more heavily than testimonial reports.

Sources

  1. mesenchymal stem cells Parkinson's disease clinical trial — Published human MSC studies in Parkinson's disease.
  2. mesenchymal stromal cells Parkinson disease — Registered Parkinson's cell therapy trials.
  3. UPDRS placebo response Parkinson clinical trials — Why placebo response complicates uncontrolled reports.

Citation practice and source hierarchy: How we evaluate evidence.

Related clinical questions

Want this reviewed for your own case?

Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.

Request a medical review · Check candidacy in 6 questions

How to cite this page

This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.

How to cite this page
StyleCitation
APAStemCell Longevita. (2026). What can MSC therapy realistically offer in Parkinson's disease?. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/parkinsons-what-msc-therapy-can-and-cannot-do
VancouverStemCell Longevita. What can MSC therapy realistically offer in Parkinson's disease? [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/parkinsons-what-msc-therapy-can-and-cannot-do

BibTeX:

@techreport{longevita_parkinsons_what_msc_therapy_can_and_cannot_do_2026,
  title       = {What can MSC therapy realistically offer in Parkinson's disease?},
  author      = {{StemCell Longevita}},
  institution = {StemCell Longevita},
  year        = {2026},
  url         = {https://stemcelllongevita.com/clinical-decisions/parkinsons-what-msc-therapy-can-and-cannot-do},
  urldate     = {2026-08-23}
}

Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite

Related pages